Post by
Msabundance on Nov 23, 2020 4:08am
FSD Pharma's leadership
The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
Comment by
Msabundance on Nov 23, 2020 7:20am
The offering has been made pursuant to an effective shelf registration statement (including a prospectus) on Form F-10 that the Company has previously filed with the U.S. Securities and Exchange Commission (the “SEC”).
Comment by
Slasher94 on Nov 23, 2020 10:06pm
This post has been removed in accordance with Community Policy
Comment by
Slasher94 on Nov 25, 2020 10:42pm
This post has been removed in accordance with Community Policy
Comment by
Slasher94 on Nov 23, 2020 10:09pm
This post has been removed in accordance with Community Policy
Comment by
wendhie05 on Nov 26, 2020 11:34am
Without this team, FSD Pharma wouldn't get this far, providing us 100% trusted products.
Comment by
Mil_Man54 on Nov 26, 2020 11:37am
I guess you've switched to your other account Bonvoyage12....pumping this and TRIP.....pick an account....be proud of your pumping....clown
Comment by
Renofund on Nov 26, 2020 12:05pm
wendhie, your script needs some fine tuning - try again